Chronic GVHD therapies offer hope for treating refractory diseaseFebruary 17, 2021TransplantMyelodysplastic SyndromeMultiple MyelomaALLAMLDLBCLB Cell Lymphoma
Extended virus shedding after COVID-19 in some patients with cancerDecember 10, 2020Patient & Survivor CareCOVID-19 UpdatesTransplantMultiple MyelomaMyelodysplastic Syndrome
In MDS, transplant ups survival in elderly and may be reimbursedDecember 5, 2020Myelodysplastic Syndrome
Prevention of HMA failure a goal for high-risk MDS posttransplantNovember 13, 2020TransplantAMLMyelodysplastic Syndrome
Are HMAS appropriate for posttransplant maintenance in acute leukemias?November 5, 2020ALLTransplantAMLMyelodysplastic Syndrome
HMAs plus novel agents may improve outcomes in higher-risk MDSSeptember 16, 2020Myelodysplastic Syndrome
ASH tackles COVID-19 with hematology-related FAQ, promotes new registriesApril 14, 2020COVID-19 UpdatesAnemiaMultiple MyelomaMyelodysplastic SyndromeT Cell Lymphomas
Second transplant a good salvage option for children with ALL, AML, or MDSMarch 16, 2020TransplantALLAMLMyelodysplastic Syndrome
Genetic analysis highlights value of germline variants in MDS, AMLSeptember 18, 2019AMLMyelodysplastic Syndrome
Durable transfusion independence in MDS with imetelstatJune 18, 2019Myelodysplastic SyndromeTransfusion Medicine
Antibody targeting ‘do not eat me’ signals is active in AML, MDSJune 11, 2019AMLMyelodysplastic Syndrome
More abnormal cells linked to poorer ASCT outcomes in MDSMay 3, 2019Myelodysplastic SyndromeTransplant
